Vicapsys Life Sciences, Inc. SEC filings VICP
Vicapsys Life Sciences, Inc. has 92 filings in SEC EDGAR's recent list, going back to Jul 17, 2009. Its latest annual report, Form 10-K, was filed on Oct 21, 2024 for the period ended Dec 31, 2023. The latest quarterly report (Form 10-Q) was filed on Jan 10, 2025, covering the quarter ended Sep 30, 2024. The most recent current report (Form 8-K) was filed on Dec 27, 2023 (material agreement, new debt). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 15-12G | Deregistration | Mar 27, 2025 | — |
| 10-Q | Quarterly report | Jan 10, 2025 | Sep 30, 2024 |
| 10-Q | Quarterly report | Jan 10, 2025 | Jun 30, 2024 |
| 10-Q | Quarterly report | Jan 10, 2025 | Mar 31, 2024 |
| 10-K | Annual report | Oct 21, 2024 | Dec 31, 2023 |
| SEC STAFF ACTION | Filing | Jun 27, 2024 | — |
| 8-K |
Current report
Material agreement, New debt
|
Dec 27, 2023 | Dec 26, 2023 |
| 10-Q | Quarterly report | Nov 14, 2023 | Sep 30, 2023 |
| 10-Q | Quarterly report | Aug 14, 2023 | Jun 30, 2023 |
| DEF 14C | Information statement | Aug 9, 2023 | Aug 9, 2023 |
| PRE 14C | Filing | Jul 28, 2023 | Jul 28, 2023 |
| D | Filing | Jul 13, 2023 | — |
| S-1 | Registration statement | Jun 30, 2023 | — |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale
|
Jun 30, 2023 | Jun 27, 2023 |
| 8-K |
Current report
Material agreement
|
Jun 2, 2023 | May 31, 2023 |
| 8-K/A |
Amended current report
Auditor change
|
May 18, 2023 | May 12, 2023 |
| 8-K |
Current report
Auditor change
|
May 17, 2023 | May 12, 2023 |
| 10-Q | Quarterly report | May 15, 2023 | Mar 31, 2023 |
| 10-K | Annual report | Apr 14, 2023 | Dec 31, 2022 |
| NT 10-K | Filing | Mar 31, 2023 | Dec 31, 2022 |
| 8-K |
Current report
Officer or director change
|
Jan 12, 2023 | Jan 1, 2023 |
| DEF 14C | Information statement | Nov 21, 2022 | Nov 21, 2022 |
| 10-Q | Quarterly report | Nov 21, 2022 | Sep 30, 2022 |
| NT 10-Q | Filing | Nov 14, 2022 | Sep 30, 2022 |
| 8-K |
Current report
Officer or director change
|
Sep 28, 2022 | Sep 21, 2022 |
| 10-Q | Quarterly report | Aug 16, 2022 | Jun 30, 2022 |
| NT 10-Q | Filing | Aug 15, 2022 | Jun 30, 2022 |
| DEF 14C | Information statement | May 17, 2022 | May 17, 2022 |
| 10-Q | Quarterly report | May 13, 2022 | Mar 31, 2022 |
| PRE 14C | Filing | May 6, 2022 | May 6, 2022 |
| 8-K |
Current report
Officer or director change, Other events
|
Apr 12, 2022 | Feb 15, 2022 |
| 10-K | Annual report | Mar 16, 2022 | Dec 31, 2021 |
| 10-Q | Quarterly report | Nov 12, 2021 | Sep 30, 2021 |
| 10-Q | Quarterly report | Sep 20, 2021 | Jun 30, 2021 |
| 10-Q | Quarterly report | Sep 20, 2021 | Mar 31, 2021 |
| 10-K | Annual report | Sep 17, 2021 | Dec 31, 2020 |
| 10-Q | Quarterly report | Sep 13, 2021 | Sep 30, 2020 |
| 10-Q | Quarterly report | Sep 9, 2021 | Jun 30, 2020 |
| 10-Q | Quarterly report | May 15, 2020 | Mar 31, 2020 |
| UPLOAD | Letter from the SEC | Apr 6, 2020 | — |
| 10-12G/A | Filing | Mar 30, 2020 | — |
| UPLOAD | Letter from the SEC | Mar 27, 2020 | — |
| CORRESP | Letter to the SEC | Mar 20, 2020 | — |
| 10-12G/A | Filing | Mar 20, 2020 | — |
| UPLOAD | Letter from the SEC | Mar 11, 2020 | — |
| 10-12G | Filing | Feb 12, 2020 | — |
| D | Filing | Feb 16, 2018 | — |
| D | Filing | Jan 8, 2018 | — |
| 15-15D | Filing | Nov 7, 2016 | — |
| 10-Q | Quarterly report | Aug 24, 2010 | Jun 30, 2010 |
| NT 10-Q | Filing | Aug 16, 2010 | Jun 30, 2010 |
| 8-K/A |
Amended current report
Acquisition or sale of assets
|
Jul 29, 2010 | May 13, 2010 |
| 8-K |
Current report
Officer or director change
|
Jul 1, 2010 | Jun 30, 2010 |
| 10-Q | Quarterly report | Jun 22, 2010 | Mar 31, 2010 |
| D | Filing | May 25, 2010 | — |
| 10-K | Annual report | May 24, 2010 | Dec 31, 2009 |
| D | Filing | May 24, 2010 | — |
| 8-K |
Current report
Acquisition or sale of assets, Unregistered share sale
|
May 18, 2010 | May 13, 2010 |
| NT 10-Q | Filing | May 17, 2010 | Mar 31, 2010 |
| 8-K |
Current report
Agreement ended, Officer or director change
|
Apr 26, 2010 | Apr 20, 2010 |
| 8-K |
Current report
Officer or director change
|
Apr 12, 2010 | Apr 8, 2010 |
| NT 10-K/A | Filing | Apr 2, 2010 | Dec 31, 2009 |
| NT 10-K | Filing | Apr 1, 2010 | Dec 31, 2009 |
| EFFECT | Filing | Dec 9, 2009 | — |
| 8-K |
Current report
Other events
|
Dec 9, 2009 | Dec 9, 2009 |
| UPLOAD | Letter from the SEC | Dec 9, 2009 | — |
| UPLOAD | Letter from the SEC | Dec 9, 2009 | — |
| CORRESP | Letter to the SEC | Dec 3, 2009 | — |
| S-1/A | Amended registration statement | Nov 20, 2009 | — |
| S-1/A | Amended registration statement | Oct 27, 2009 | — |
| CORRESP | Letter to the SEC | Sep 29, 2009 | — |
| S-1/A | Amended registration statement | Sep 29, 2009 | — |
| UPLOAD | Letter from the SEC | Aug 11, 2009 | — |
| S-1 | Registration statement | Jul 17, 2009 | — |
Showing 74 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- VICP (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- FL
- Headquarters
- Cumming, GA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1468639
- Former names
- SSGI, INC. (until Nov 7, 2016)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.